Neuritogenesis induced by vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide, and peptide histidine methionine in SH-SY5y cells is associated with regulated expression of cytoskeleton mRNAs and proteins.
Vasoactive intestinal peptide (VIP) and the related peptides pituitary adenylate cyclase-activating polypeptide (PACAP) and peptide histidine methionine (PHM) are known to regulate proliferation and/or differentiation in normal and tumoral cells. In this study, neuritogenesis in human neuroblastoma SH-SY5Y cells cultured in serum-free medium was induced by VIP, PACAP, and PHM. The establishment of this process was followed by the quantification of neurite length and branching and the expression of neurofilament mRNAs, neurofilament proteins, and other cytoskeletal protein markers of neuronal differentiation: neuron-specific MAPs and beta-tubulin III. Neurite length and branching and the expression of most markers tested were increased by VIP and PACAP in a similar, although slightly different, fashion. In contrast, neuritic elongation induced by PHM was correlated with neither an increase in branching or neurofilament mRNAs nor a clear change in the expression of cytoskeleton proteins, with the exception of the stimulation by PHM of doublecortin, a microtubule-associated marker of migrating neuroblasts. These findings are the first evidence from a human neuron-like cell line for 1) a direct regulation of the metabolism of neurofilaments by VIP and PACAP and 2) the induction by PHM of neuritic processes of an apparent immature character.
Héraud
Céline
C
Laboratoire des Biomembranes et Signalisation Cellulaire, Poitiers, France.
Hilairet
Sandrine
S
Muller
Jean-Marc
JM
Leterrier
Jean-François
JF
Chadéneau
Corinne
C
D015153:Blotting, Western; D002454:Cell Differentiation; D045744:Cell Line, Tumor; D003599:Cytoskeleton / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D016501:Neurites / Q000187:drug effects* / Q000502:physiology; D016900:Neurofilament Proteins / Q000187:drug effects / Q000502:physiology; D009479:Neuropeptides / Q000494:pharmacology*; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010451:Peptide PHI / Q000494:pharmacology*; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*
C495401:ADCYAP1 protein, human; D016900:Neurofilament Proteins; D009479:Neuropeptides; D018696:Neuroprotective Agents; D010451:Peptide PHI; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D014660:Vasoactive Intestinal Peptide